Talk:Brilaroxazine
| This is the talk page for discussing improvements to the Brilaroxazine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Brilaroxazine.
|
good to add history
edit"Reviva’s lead drug candidate, brilaroxazine (RP5063), is a multimodal modulator of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT7 receptors and D2, D3, D4 dopamine receptors in clinical development for multiple neuropsychiatric indications including schizophrenia, bipolar disorder, major depressive disorder (MDD), psychotic and agitation symptoms in dementia or Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD). Beyond its use in CNS disorders, brilaroxazine has also been granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for development in two respiratory indications in which serotonin signaling plays a central role in triggering pathology—pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF)."
https://www.nature.com/articles/d43747-021-00068-0